To ackowledge the TMF in your publications, copy and paste the language below
The authors acknowledge the support of the Chao Family Comprehensive Cancer Center Transgenic Mouse Facility Shared Resource, supported by the National Cancer Institute of the National Institutes of Health under award number P30CA062203. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
What do we do ?
The UC Irvine Transgenic Mouse Facility (TMF) core facility provides services for the design, generation, breeding, genotyping, importing, and preserving genetically-modified mice and embryonic stem cells. In addition to academic clients at UCI, we support academic investigators at several other sister UC-campuses and numerous other universities throughout the USA as well as providing these services to commercial clients. The TMF's research associates have a combined 130 years of experience in generation of genetically engineered mice. Our experience can be your advantage.
How can we assist you ?
- Finding and importing genetically modified mice ? Designing and generating genetically modified mice ?
- Designing a targeting vector
- Breeding
- Genotyping
- What strain of mice did this ES cell line come from? (PDF)
Got a question? Email the TMF - we're here to help!
The TMF uses iLab to provide estimates and billing of services
- Inquiries regarding services and projects can still be submitted using the 'Email the TMF' link above.
- Register with iLab here. For questions about registration, please e-mail Medalyn Supnet.
- Download an iLab user guide for the TMF.
Of interest to TMF and Cancer Center users
The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice. (2021) Current Opinion in Genes & Development 66:57-62.
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. (2020) Science Advances 6, doi: 10.1126/sciadv.abc9450
Near-Infrared dual bioluminescence imaging in mouse models of cancer using infraluciferin (2019) eLife https://doi.org/10/7554/eLife.45801.001
Is your gRNA not mediating cutting ? Maybe inclusion of a 'TT' or 'GCC' sequence in the seed domain is the reason ? (2019) Cell Reports 26, p1098
Nucleosomes inhibit target cleavage by CRISPR-CAS9 in vivo - a possible reason why targeting efficiency varies from locus to locus. (2018) PNAS 38, p9351.
Transgenic Mouse Models in Cancer Research - a review of methods to generate mouse models of human cancer and examples of their use. (2018) Frontiers in Oncology 8:268